Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 13/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.61 |
| ▸ | PGR | P06401 | 4/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL6 | P05231 | 1/20 | 0.56 |
| ▸ | GLUL | P15104 | 1/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27571456 | 0.99 | HIF1A (0.61) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| SCHEMBL27941428 | 0.99 | HIF1A (0.61) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| SCHEMBL23456330 | 0.98 | HIF1A (0.59) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| SCHEMBL6001323 | 0.97 | HIF1A (0.65) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| SCHEMBL14931695 | 0.96 | HIF1A (0.64) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| SCHEMBL249836 | 0.96 | HIF1A (0.64) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| Butyric Acid SCHEMBL28140488 | 0.95 | HIF1A (0.59) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| SCHEMBL1535104 | 0.94 | HIF1A (0.63) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| Valeric Acid SCHEMBL28435896 | 0.93 | HIF1A (0.57) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR | |
| Propionic Acid SCHEMBL27929927 | 0.93 | HIF1A (0.59) | HIF1ASMN1; SMN2HSD17B10NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408110-A1 | PHARMACEUTICAL HYDROCORTISONE SOLUTION FOR INJECTION DEVICE | CROSSJECT (FR) | 2024-12-12 | — | — | US | claimed |
| EP-4429634-A1 | PHARMACEUTICAL SOLUTION OF HYDROCORTISONE FOR INJECTION DEVICE | Crossject (FR) | 2024-09-18 | — | — | EP | claimed |
| CN-118251209-A | Hydrocortisone pharmaceutical solution for injection device | 克鲁斯杰克特公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2023083825-A1 | PHARMACEUTICAL SOLUTION OF HYDROCORTISONE FOR INJECTION DEVICE | CROSSJECT (FR) | 2023-05-19 | — | — | WO | claimed |
| EP-3532033-B1 | PHARMACEUTICAL HYDROCORTISONE SOLUTION FOR AN INJECTION DEVICE | CROSSJECT (FR) | 2020-08-05 | — | — | EP | claimed |
| US-10456355-B1 | Pharmaceutical hydrocortisone solution for an injection device | CROSSJECT (FR) | 2019-10-29 | — | — | US | claimed |
| US-20190314273-A1 | PHARMACEUTICAL HYDROCORTISONE SOLUTION FOR AN INJECTION DEVICE | CROSSJECT (FR) | 2019-10-17 | — | — | US | claimed |
| EP-3829591-B1 | HYDROCORTISONE FOR THE TREATMENT OF MASTITIS IN NON-HUMAN MAMMALS | VIRBAC (FR) | 2026-05-27 | — | — | EP | disclosed |
| US-20260091042-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | ANTARES PHARMA, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12521404-B2 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | ANTARES PHARMA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12478629-B2 | Use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals | VIRBAC (FR) | 2025-11-25 | — | — | US | disclosed |
| WO-2025136950-A1 | MIXING AND DELIVERY SYSTEMS AND NEEDLE HUBS FOR SAME | SOLUtion Medical, Inc. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4496575-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | Antares Pharma, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| US-9693956-B2 | Liquid compositions capable of foaming and including active agents, and methods for making or developing same | MIKA PHARMA GMBH | 2017-07-04 | — | — | US | disclosed |
| US-20160022579-A1 | Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same | MIKA PHARMA GMBH | 2016-01-28 | — | — | US | disclosed |
| US-9005626-B2 | Liquid compositions capable of foaming and including active agents, and methods for making or developing same | MIKA PHARMA GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20110269704-A1 | METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY | MIKA PHARMA GESELLSCHAFT FUR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110059117-A1 | Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same | MIKA PHARMA GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20080255125-A1 | Topically Applied Medicament for Animals | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| CN-1759043-A | Safety containers for biologically active substances and method for producing said container | BAXTER HEALTHCARE SA (CH) | 2006-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091042-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF HYDROCORTISONE SODIUM PHOSPHATE AND MONOTHIOGLYCEROL | NR3C1, HSD11B2, NR3C2 | HIF1A 1532/4885SMN1; SMN2 4758/4885HSD17B10 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.